About this trial
This multi-center, randomized controlled trial is designed to evaluate clinical effectiveness and cost-effectiveness of ESD for undifferentiated type of EGC meeting the expanded indication compared with surgery.
Eligibility criteria
Qualifiers
Patients who are diagnosed with undifferentiated type EGC (signet ring cell carcinoma, poorly differentiated tubular adenocarcinoma, or poorly cohesive carcinoma) that meets the expanded indication of ESD 1) Tumor confined to the mucosa without ulcer, and size ≤2 cm on endoscopic evaluations 2) No evidence of lymph node metastasis and distant metastasis on abdominal CT scan
Adult patients aged 19-75 years
Patients who had willingness to sign an informed consent form
Disqualifiers
Patient age: < 19 years or age > 75 years
Diagnosis and active treatment for other organ cancer except carcinoma in situ and non-melanomatous skin cancer within 5 years
Previous gastrectomy or esophagectomy history
Multiple gastric cancers
Trial design
Treatments tested in this trial
- Endoscopic submucosal dissection
- Surgery
Treatment groups
Sponsors and collaborators
National Cancer Center, Korea
Lead sponsor
Seoul St. Mary's Hospital, The Catholic University
Collaborator
Chilgok Kyungpook National University Hospital
Collaborator
Pusan National University Hospital
Collaborator
Samsung Medical Center
Collaborator
Severance Hospital, Yonsei University College of Medicine
Collaborator
Gangnam Severance Hospital, Yonsei University College of Medicine
Collaborator
Asan Medical Center
Collaborator
Chonnam National University Hospital
Collaborator